It has been observed that concentrations of CD133+ CD326- EVs decrease when lung cancer patients respond to anticancer therapy (Brocco et al., 2019), and lower levels of circulating CD133+ CD336- EVs in peripheral blood from lung cancer patients are associated with longer survival times compared with patients with higher levels (Brocco et al., 2019). The gene discussed is PROM1; the disease is lung cancer.